Application of therapeutic isotope labeled Evans blue and its derivatives in preparing tumor targeted radiotherapy medicaments

An isotope-labeled, tumor-targeting technology, which is applied in the field of therapeutic isotope-labeled Evans blue and its derivatives in the preparation of tumor-targeted radiotherapy drugs, can solve the problem of high cost, easy failure, and poor clinical effect And other issues

Inactive Publication Date: 2013-04-17
JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, most of the carriers in tumor internal irradiation drugs are macromolecular protein molecules. This type of drug is a macromolecular compound, which is immunogenic and easy to be cleared by the reticuloendothelial system. It is expensive and prone to failure
poor clinical effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of therapeutic isotope labeled Evans blue and its derivatives in preparing tumor targeted radiotherapy medicaments
  • Application of therapeutic isotope labeled Evans blue and its derivatives in preparing tumor targeted radiotherapy medicaments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] 131 I Mark Evans Blue Treatment W 256 Tumor Rat Effect Study

[0023] Materials and Methods:

[0024] SD rats were purchased from Shanghai Slack Experimental Animal Co., Ltd.; 131-iodine was purchased from Atomic Hi-Tech Co., Ltd.; Evans blue was purchased from Sinopharm Group.

[0025] Subcutaneous implantation of solid tumor mice: Inject 0.1 mL of peritoneal fluid containing rat W256 tumor cells into the subcutaneous area of ​​the axilla of the implanted rats. After 5 days, tumor masses form. The tumors are selected from tumor-bearing mice with a maximum diameter of 1.0±0.2 Twenty-four tumor-bearing rats between cm were used in the experiment, and they were randomly divided into 4 groups according to the tumor size, 6 rats / group. The blank group was not treated, and the other three treatment groups were injected intravenously with radiation doses of 1, 2, and 5 mCi / Kg respectively. 131 I mark Evans blue.

[0026] Efficacy observation According to the predetermin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to therapeutic isotope labeled Evans blue and its derivatives. The compound contains a chemical element or isotope with an unstable nucleus. During the decay of the compound into a stable state, radiation can be emitted, and the radiation is sufficient to destroy adjacent cells or tissues so as to be used for targeted radiotherapy, thus improving the curability of warm-blooded animals receiving necrosis induced anti-tumor treatment. The invention has a special advantage that after tumor treatment through chemotherapy and physical methods, live edges can be supplemented by therapeutically and radioactively labeled Evans blue in single or multiple doses so as to improve curability. Necrosis induced treatment cases include, for example, minimally invasive tumor ablationconducted by chemical methods like percutaneous ethanol or acetic acid injection, or by physical methods like cryotherapy, microwave, focused ultrasound, interstitial laser therapy and radiofrequencyablation; chemotherapy utilizing cytotoxic drugs or vascular targeting agents (VTA ); as well as external or internal radiotherapy.

Description

field of invention [0001] The invention relates to the application of therapeutic isotope-labeled Evans blue and its derivatives in the preparation of tumor-targeted radiotherapy drugs Background of the invention [0002] Malignant tumors are still a serious threat to human health. Except for early detection and surgical resection, there is no definite cure. However, most patients have advanced to the middle and late stages when they see a doctor. Exploring and developing effective anticancer therapies is the top priority of medical research Heavy. All the antineoplastic drugs currently used clinically have different degrees of toxic and side effects, and targeted therapy is an effective way to solve this problem. Targeted therapy drugs only treat abnormal parts of tumor cells or tissues, and have low adverse reactions and good curative effects. This type of drug is the development trend of tumor treatment. [0003] At present, most of the carriers in tumor internal irradi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K51/04A61P35/00A61K101/02A61K103/00A61K103/10A61K103/30A61K103/32A61K103/34
Inventor 倪以成张健孙自平孔铭姚楠朱佳蒋翠花
Owner JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap